Highlights

Join Nostrum at DDC Europe 2026 in Barcelona: our CSO Víctor Guallar speaking and the Nostrum DDC After Event

Meet us at DDC Europe 2026 in Barcelona (10-12 Nov): our CSO Víctor Guallar is speaking, and Nostrum hosts the DDC After Event on 10 Nov at 19:30h, InterContinental Hotel, Sala Serrat.

Expanding our reach: Nostrum Biodiscovery in Boston and Japan

From Discovery on Target in Boston to the EU-Japan Centre in Osaka, Shonan iPark and BioJapan

Nostrum Biodiscovery at Enamine’s 35th Anniversary Conference

Manel Gil Sorribes and Ferran Planas on navigating ultra-large chemical libraries with AI and physics

New paper in Nature Communications: seeking the physical code of DNA

hexABC seeking the physical code of DNA

Nostrum Biodiscovery Sponsoring the Alchemistry Free Energy Workshop 2026

Nostrum Biodiscovery Sponsoring the Alchemistry Free Energy Workshop 2026

Nostrum Biodiscovery Appoints Ahmad Reza Saadat as Head of Business Development, United States

Experienced life sciences executive joins Nostrum's Boston office to lead North American commercial expansion

Nostrum’s Protein Engineering Department at the top of a Protein Binder Design Competition

Nostrum’s Protein Engineering Department at the top of a Protein Binder Design Competition

New paper in the Journal of Chemical Information and Modeling: how well can we dock PROTACs?

How Feasible Is Docking of PROTACs to POI-E3L Complexes? Testing Physics-Based and ML-Based Docking Tools

New paper in PNAS Nexus: molecular simulations explain the origin of a rare disease

Molecular simulations meet personalized medicine: the mechanism of action of CLC-5 antiporter and the origin of Dent's disease

Our Protein Engineering Director, Sergi Rodà, has published a new article in Trends in Biotechnology

Computationally Guided Genome Rewiring of Escherichia coli for PET Biodegradation and Upcycling

Nostrum Biodiscovery on the Global Stage: Upcoming Presentations by Our Team

We are delighted to announce that Laura Reyes, Helena Martin, and Víctor Guallar will represent Nostrum Biodiscovery at a series of major international conferences in the biotechnology, RNA therapeutics, oligonucleotide, and protein degradation sectors. These events are key opportunities for networking, showcasing our innovation, and forging new collaborations across the global life sciences community.

New paper in Communications Chemistry: generative AI meets physics to design active CDK2 inhibitors

Optimizing drug design by merging generative AI with a physics-based active learning framework

MAY 2025- Our Co-Founder, Modesto Orozco, has published a new paper in Nature Methods

Over 100 researchers have published an article in Nature Methods advocating for a transformative change in how molecular dynamics (MD) data is handled.

MARCH 2025 - Our Nucleic Acid Director, Vito Genna, has published a new paper in Nucleic Acid Research

The findings unveil a remarkable inclination—of both the human genome and transcriptome—to generate hybrid triplex formation, particularly within untranslated (UTRs) and regulatory regions, thereby corroborating the existence of a triplex-mediated regulatory mechanism.

MARCH 2025 - Find us at the MWC in Barcelona, 3-6 March

We look forward to exploring the latest innovations in computational drug discovery and engaging in insightful conversations. Excited to share how our solutions are contributing to the future of biotech.

FEB 2025 - We are expanding to Boston (USA) !

We’re thrilled to announce the opening of our new offices in Boston, USA—a major milestone in our journey. As a biotech company dedicated to innovation in molecular modeling and design, this move places us at the heart of one of the world’s leading life sciences hubs and closer to our key partners, clients, and collaborators.

FEB 2025 - Latest release of PELE 1.9, now featuring PELE Loop Closure

We are thrilled to announce the latest release of PELE 1.9, now featuring PELE Loop Closure, designed to improve the conformational exploration of flexible loops in proteins and RNA.

FEB 2025 - Thrilled to be part of the Programa Desafia Boston !

What an incredible first day kicking off our journey to Boston with the Programa Desafía! We are beyond excited to be part of this initiative, which will equip us with the tools, insights, and connections needed to successfully expand our reach in the U.S. market. This program marks a significant step in our global expansion, and we can’t wait to see what lies ahead!

JAN 2025 - Our President and co-founder Modesto Orozco awarded an ICREA Academia grant

We are excited to share that our president and co-founder, Modesto Orozco, has been awarded an ICREA Academia distinction for the 2024 call. These grants, awarded by the Catalan Institution for Research and Advanced Studies (ICREA), aim to promote research talent in Catalan universities.

JAN 2025 - Newsletter Q4 2024

Our latest newsletter is here ! Learn about what we have been up to this last quarter of 2024. ‍

NOV 2024 - Sergi Roda presenting the latest in Enzyme Engineering at the Green Innovation Forum 2024 in Pamplona

Join us to discover and learn in detail how biotechnology can provide solutions towards a more sustainable, carbon neutral and greener economic model. Meet our Head of Protein Engineering, @ Sergi Roda, who will present our solutions for scalable PET degrading enzymes in his pitch presentation :”Leveraging computational protein design to tackle polymer biodegradation”

DEC 2024 - Victor Guallar (CSO) speaking at the DDC Conference, Barcelona, 3-5 Dec

The DDC will be happening in Barcelona for the first time, Dec3-5. One of the best drug discovery conferences crossing the Atlantic and landing in Europe. Do not miss this chance to listen to great talks, exchange and network. Our CSO Victor Guallar, also the group leader of the EAPM lab at BSC, will be one of the speakers. He will discuss the potential of AI for polypharmacology, and how we are exploring this path at Nostrum Biodiscovery.

NOV 2024 - HubXchange Conference, Brussels, 18-21 Nov

Meet our team at the next hubXchange in Brussels from November 18 to 21 ! Our director of AI, Alexis Molina, will be presenting the latest on informed lead generation from the screening of ultra-large databases. Alexis will also be presenting the work done with our director of Protein engineering, Sergi Rodà , on antibody engineering. Finally, our director of Nucleic Acids, Vito Genna, will present XNAHub®, a platform to investigate natural and non-natural oligonucleotides. Our Business Development team will be on-site, alongside our directors presenting their latest innovations in drug discovery and therapeutics. Don't hesitate to reach out Helena Martín Hernández and Laura Reyes to dive into how our team can support your projects.

NEWSLETTER Nº3

A Newsletter to inform about the Q2 2024🎊

JULY 2024 - Interview with Carme Almansa

"Do not be afraid of change, it is always an opportunity. Never lose the capacity to think outside the box"

GeoDirDock (GDD): our new diffusion model for directed docking

NEWSLETTER Nº2

A Newsletter to inform about the Q1 2024🎊

APRIL 2024 - Interview with Modesto Orozco (president and co-founder)

"It couldn't have been anything else. I always wanted to be a scientist; there was no option two"

NEWSLETTER Nº1 - WELCOME, DISCOVERERS

To celebrate our 8th anniversary, we launch our Newsletter! Free Molecular Simulator and more

NOVEMBER 2023 - Interview with Pepa Limeres (Fundacion Botin)

"Nostrum Biodiscovery is one of our most paradigmatic success stories"

SEPTEMBER 2023 / NOSTRUM & NAVIGO: RESEARCH COLLABORATION

We are excited to announce a pioneering partnership between Nostrum Biodiscovery and Navigo Proteins

JUNE 2023 / NOSTRUM WEB APP : RUN FREE MOLECULAR MODELING SIMULATIONS !

We are thrilled to announce the release of Nostrum Web App, a completely free service that gives you a glimpse into selected features of our NBDSuite. You can now directly access and explore drug design workflows such as Induced-Fit docking and ADMET predictions right from your browser. Visit our website to try it out and experience the convenience of our platform.

JUNE 2023 / OUR CSO AND CO-FOUNDER VICTOR GUALLER SPEAKING AT THE NEXT-GENERATION DEGRADERS & GLUES CONFERENCE, LONDON, 20-22 JUNE

Finding hits, even for molecular glues, might no be a problem anymore with modern virtual screening. The main problem now shifts to generating the right target, and we might have the best in silico modeling solution for ligase screening and target generation.

APRIL 2023 / NOSTRUM BIODISCOVERY TAKES PART IN THE MDDB EUROPEAN PROJECT

Nostrum Biodiscovery is one of the key partners in the ambitious european MDDB project, which was officially launched last 24-25th of april in Barcelona. Researchers led by Dr. Modesto Orozco, co-funder and president of Nostrum Biodiscovery, and head of the Molecular Modelling and Bioinformatics lab at IRB Barcelona, aim to develop the first European database of molecular dynamics. In the upcoming three years, the scientists will establish the groundwork for an infrastructure that enhances the use of computational resources, enables data analysis from multiple perspectives, ensures rapid and efficient information exchange among various institutions, and promotes the incorporation of molecular dynamics into other research domains.

APRIL 2023 / ENAMINE & NOSTRUM BIODISCOVERY COLLABORATION

We are excited to announce a game-changing partnership between Nostrum Biodiscovery, a frontrunner in computational drug discovery services, and ENAMINE, a worldwide supplier of chemical building blocks and screening compounds. These two powerhouses are joining forces to co-develop a cutting-edge search engine specifically for the REAL Space billion database, delivering unprecedented performance in searching vast chemical spaces with minimal computational resources.

FURENPOL

Enzymatic synthesis and recycling of bio-based furanic polymers.